Patient with chronic myeloid leukemia in complete cytogenetic response: What does it mean, and what does one do next?

Journal of Clinical Oncology

Volumn 32, Issue 5, 2014, Pages 379-384

  Marin, David ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; NILOTINIB; 4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; BCR ABL1 FUSION PROTEIN, HUMAN; BCR-ABL1 FUSION PROTEIN, HUMAN; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADULT; ANGIOPLASTY; ARTICLE; ASTHENIA; BONE MARROW EXAMINATION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; INTERMITTENT CLAUDICATION; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MOLECULAR RESPONSE; PATIENT REFERRAL; PHILADELPHIA CHROMOSOME NEGATIVE CELL; POPLITEAL ARTERY; PRIORITY JOURNAL; TREATMENT RESPONSE; BLOOD; CHEMICALLY INDUCED DISORDER; CHROMOSOME ANALYSIS; DRUG ADMINISTRATION; DRUG ANTAGONISM; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHENOTYPE; PHILADELPHIA 1 CHROMOSOME; REVIEW; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ARTERIAL OCCLUSIVE DISEASES; ASTHENIA; BENZAMIDES; BONE MARROW EXAMINATION; CYTOGENETIC ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; FUSION PROTEINS, BCR-ABL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PHENOTYPE; PHILADELPHIA CHROMOSOME; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84897569767     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.9230     Document Type: Article

References (37)

1. Marin D: Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia. Hematology Am Soc Hematol Educ Program 2012:115-121, 2012
2. Kantarjian H, O'Brien S, Jabbour E, et al: Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: A single-institution historical experience. Blood 119:1981-1987, 2012
3. Cross NC, White HE, Müller MC, et al: Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26:2172-2175, 2012
4. Hughes T, Deininger M, Hochhaus A, et al: Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28-37, 2006 (Pubitemid 43990609)
5. Kaeda J, Chase A, Goldman JM: Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia. Acta Haematol 107:64-75, 2002 (Pubitemid 34264170)
6. Lin F, Chase A, Bungey J, et al: Correlation between the proportion of Philadelphia chromosome-positive metaphase cells and levels of BCR-ABL mRNA in chronic myeloid leukaemia. Genes Chromosomes Cancer 13:110-114, 1995
7. de Lavallade H, Apperley JF, Khorashad JS, et al: Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26:3358-3363, 2008
8. Marin D, Bazeos A, Mahon FX, et al: Adherence is the critical factor for achieving molecular responses in chronic myeloid leukemia patients who achieve complete cytogenetic responses on imatinib. J Clin Oncol 24:2381-2388, 2010
9. Rousselot P, Huguet F, Rea D, et al: Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109:58-60, 2007 (Pubitemid 46053043)
10. Mahon FX, Réa D, Guilhot J, et al: Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029-1035, 2010
11. Legros L, Rousselot P, Giraudier S, et al: Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response. Blood 120:1959-1960, 2012
12. Hughes TP, Kaeda J, Branford S, et al: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423-1432, 2003 (Pubitemid 37211057)
13. Druker BJ, Guilhot F, O'Brien SG, et al: Five-year follow-up of imatinib therapy for newly diagnosed chronic myelogenous leukemia in chronicphase shows sustained responses and high overall survival. N Engl J Med 355:2408-2417, 2006
14. Marin D, Milojkovic D, Olavarria E, et al: European LeukemiaNet criteria for failure or sub-optimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112:4437-4444, 2008
15. Marin D: Current status of imatinib as frontline therapy for chronic myeloid leukemia. Semin Hematol 47:312-318, 2010
16. Marin D, Ibrahim AR, Lucas CM, et al: Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 30:232-238, 2012
17. Hehlmann R, Müller MC, Lauseker M, et al: Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: Results from the randomized CML-Study IV. J Clin Oncol 32:415-423, 2014
18. Sokal JE, Cox EB, Baccarani M, et al: Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 63:789-799, 1984 (Pubitemid 14141296)
19. Thomas J, Wang L, Clark RE, et al: Active transport of imatinib into and out of cells: Implications for drug resistance. Blood 104:3739-3745, 2004 (Pubitemid 39564452)
20. White DL, Dang P, Engler J, et al: Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 26:2761-2767, 2010
21. Noens L, van Lierde MA, De Bock R, et al: Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study. Blood 113:5401-5411, 2009
22. Jabbour EJ, Kantarjian H, Eliasson L, et al: Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol 87:687-691, 2012
23. Mahon FX, Delbrel X, Cony-Makhoul P, et al: Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 20:214-220, 2002 (Pubitemid 34032614)
24. Rea D, Rousselot P, Guilhot J, et al: Curing chronic myeloid leukemia. Curr Hematol Malig Rep 7:103-108, 2012
25. Rea D, Rousselot P, Guilhot F, et al: Discontinuation of second generation (2G) tyrosine kinase inhibitors (TKI) in chronic phase (CP)-chronic myeloid leukemia (CML) patients with stable undetectable BCR-ABL transcripts. Blood 120, 2012 (abstr 916)
26. Ross DM, Branford S, Seymour JF, et al: Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study. Blood 122:515-522, 2013
27. Cullis JO, Marks DI, Schwarer AP, et al: Relapse into blast crisis following bone marrow transplantation for chronic phase chronic myeloid leukaemia: A report of five cases. Br J Haematol 81:378-382, 1992
28. Rousselot P, Charbonnier A, Cony-Makhoul P, et al: Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 32:424-430, 2014
29. Kaeda J, O'Shea D, Szydlo RM, et al: Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: An attempt to define patients who may not require further therapy. Blood 107:4171-4176, 2006 (Pubitemid 43726829)
30. Arpinati M, Tolomelli G, Bochicchio MT, et al: Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia. Biol Blood Marrow Transplant 19:735-740, 2013
31. Neelakantan P, Gerrard G, Lucas CM, et al: Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukaemia: Implications for early intervention strategies. Blood 121:2739-2742, 2013
32. Hanfstein B, Müller MC, Hehlmann R, et al: Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26:2096-2112, 2012
33. Jabbour E, Kantarjian HM, O'Brien S, et al: Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: What is the optimal response? J Clin Oncol 29:4260-4265, 2011
34. Jabbour E, Kantarjian H, O'Brien S, et al: The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 118:4541-4546, 2011
35. Eliasson L, Clifford S, Barber N, et al: Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 35:626-630, 2011
36. Wilson HS, Hutchinson SA, Holzemer WL: Reconciling incompatibilities: A grounded theory of HIV medication adherence and symptom management. Qual Health Res 12:1309-1322, 2002
37. Spoelstra SL, Given CW: Assessment and measurement of adherence to oral antineoplastic agents. Semin Oncol Nurs 27:116-132, 2011